| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Neil E Paterson, David J Balfour, Athina Marko. Chronic bupropion attenuated the anhedonic component of nicotine withdrawal in rats via inhibition of dopamine reuptake in the nucleus accumbens shell. The European journal of neuroscience. vol 25. issue 10. 2007-08-17. PMID:17561823. |
in conclusion, the bupropion-induced increase in extracellular dopamine in the nucleus accumbens shell may ameliorate the anhedonia associated with nicotine withdrawal, which in turn may facilitate smoking cessation. |
2007-08-17 |
2023-08-12 |
human |
| Ronnen H Segman, Kyra Kanyas, Osnat Karni, Elad Lerer, Tanya Goltser-Dubner, Vera Pavlov, Bernard Lere. Why do young women smoke? IV. Role of genetic variation in the dopamine transporter and lifetime traumatic experience. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. vol 144B. issue 4. 2007-08-14. PMID:17427187. |
applying a multifactorial model, we examined the role of genetic variation in the dopamine transporter (dat1) in smoking initiation (si) and nicotine dependence. |
2007-08-14 |
2023-08-12 |
human |
| Dayong Wang, Yukihiro Noda, Yuan Zhou, Akihiro Mouri, Hiroyuki Mizoguchi, Atsumi Nitta, Weiduo Chen, Toshitaka Nabeshim. The allosteric potentiation of nicotinic acetylcholine receptors by galantamine ameliorates the cognitive dysfunction in beta amyloid25-35 i.c.v.-injected mice: involvement of dopaminergic systems. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 32. issue 6. 2007-07-27. PMID:17133263. |
the effects of nicotine on the extracellular dopamine release were potentiated by galantamine, but antagonized by mecamylamine, a nachr antagonist. |
2007-07-27 |
2023-08-12 |
mouse |
| Nimish Sidhpura, Peter Redfern, Susan Wonnacot. Comparison of the effects of bupropion on nicotinic receptor-evoked [(3)H]dopamine release from rat striatal synaptosomes and slices. European journal of pharmacology. vol 567. issue 1-2. 2007-07-27. PMID:17477919. |
tobacco smoking is a nicotine addiction, mediated in part by the ability of nicotine to elicit dopamine release, as a result of the stimulation of nicotinic acetylcholine receptors associated with dopaminergic pathways. |
2007-07-27 |
2023-08-12 |
rat |
| Anne-Sophie Villégier, Shahrdad Lotfipour, Susan C McQuown, James D Belluzzi, Frances M Lesli. Tranylcypromine enhancement of nicotine self-administration. Neuropharmacology. vol 52. issue 6. 2007-07-23. PMID:17412372. |
moreover, an increase in extracellular dopamine in the nucleus accumbens was detected, using microdialysis, following nicotine (60 microg/kg) injection in tranylcypromine pre-treated rats. |
2007-07-23 |
2023-08-12 |
rat |
| Sanna Janhunen, Liisa Ahte. Differential nicotinic regulation of the nigrostriatal and mesolimbic dopaminergic pathways: implications for drug development. Neuroscience and biobehavioral reviews. vol 31. issue 3. 2007-06-28. PMID:17141870. |
comparison of nicotine and epibatidine, two nachr agonists whose relative affinities for various nachr subtypes differ, revealed differences in the nachr-mediated regulation of dopaminergic activation between these dopamine systems. |
2007-06-28 |
2023-08-12 |
Not clear |
| Eriko Higashi, Miki Nakajima, Miki Katoh, Shogo Tokudome, Tsuyoshi Yoko. Inhibitory effects of neurotransmitters and steroids on human CYP2A6. Drug metabolism and disposition: the biological fate of chemicals. vol 35. issue 4. 2007-06-06. PMID:17237153. |
cotinine formation from nicotine was inhibited by tryptamine (k(i) = 0.7 microm, competitive), serotonin (k(i) = 272 microm, noncompetitive), dopamine, noradrenaline, and adrenaline (k(i) = 11 microm, 54 microm, and 81 microm, uncompetitive). |
2007-06-06 |
2023-08-12 |
human |
| Colin O'Gara, John Stapleton, Gay Sutherland, Camila Guindalini, Ben Neale, Gerome Breen, David Bal. Dopamine transporter polymorphisms are associated with short-term response to smoking cessation treatment. Pharmacogenetics and genomics. vol 17. issue 1. 2007-05-31. PMID:17264803. |
to examine the association between polymorphisms in the dopamine transporter gene (slc6a3, dat1) and treatment outcome in smokers attempting to quit using either nicotine replacement therapy or bupropion. |
2007-05-31 |
2023-08-12 |
Not clear |
| Jennifer E Murray, Rick A Bevin. Behavioral and neuropharmacological characterization of nicotine as a conditional stimulus. European journal of pharmacology. vol 561. issue 1-3. 2007-05-22. PMID:17343849. |
some behavioral effects of nicotine have been attributed to dopamine and glutamate. |
2007-05-22 |
2023-08-12 |
rat |
| N Hamdani, J Ades, P Gorwoo. [Heritability and candidate genes in tobacco use]. L'Encephale. vol 32. issue 6 Pt 1. 2007-05-18. PMID:17372541. |
genetic polymorphisms of the dopamine d1, d2, d4 and d5 receptors, dopamine transporter (dat1) and dopamine b-hydroxylase (dbh) have been associated at least once with clinical aspects of tobacco use (initiation, dependence and intensity) and temperament traits as novelty seeking, the latter being lower in smokers and thus considered as a vulnerable marker in accordance with the reinforcement effect of nicotine. |
2007-05-18 |
2023-08-12 |
human |
| Lucyna Antkiewicz-Michaluk, Jerzy Michaluk, Irena Romańska, Piotr Popik, Martyna Krawczyk, Irena Nalepa, Jerzy Vetulan. Nicotine potentiates imipramine-induced effects on catecholamine metabolism: possible relation to antidepressant activity. Pharmacological reports : PR. vol 58. issue 6. 2007-05-11. PMID:17220541. |
following our behavioral studies demonstrating augmentation of imipramine action by concomitant administration of nicotine, we investigated the effects of one or 14 days of treatment (twice daily) with imipramine and nicotine on dopamine metabolism in various brain areas of rat and noradrenaline in the brain stem. |
2007-05-11 |
2023-08-12 |
rat |
| Lucyna Antkiewicz-Michaluk, Jerzy Michaluk, Irena Romańska, Piotr Popik, Martyna Krawczyk, Irena Nalepa, Jerzy Vetulan. Nicotine potentiates imipramine-induced effects on catecholamine metabolism: possible relation to antidepressant activity. Pharmacological reports : PR. vol 58. issue 6. 2007-05-11. PMID:17220541. |
as revealed by hplc, dopamine metabolism in the nucleus accumbens was slightly decreased after 14 days of treatment with imipramine, and co-administration of nicotine resulted in a significant and much more pronounced depression of dopamine metabolism in all investigated dopaminergic structures. |
2007-05-11 |
2023-08-12 |
rat |
| Lucyna Antkiewicz-Michaluk, Jerzy Michaluk, Irena Romańska, Piotr Popik, Martyna Krawczyk, Irena Nalepa, Jerzy Vetulan. Nicotine potentiates imipramine-induced effects on catecholamine metabolism: possible relation to antidepressant activity. Pharmacological reports : PR. vol 58. issue 6. 2007-05-11. PMID:17220541. |
the biochemical response to apomorphine in terms of dopamine metabolism was not changed by chronic administration of the investigated drugs but noradrenaline metabolism in the brain stem was strongly attenuated after a combined treatment of imipramine and nicotine. |
2007-05-11 |
2023-08-12 |
rat |
| Lucyna Antkiewicz-Michaluk, Jerzy Michaluk, Irena Romańska, Piotr Popik, Martyna Krawczyk, Irena Nalepa, Jerzy Vetulan. Nicotine potentiates imipramine-induced effects on catecholamine metabolism: possible relation to antidepressant activity. Pharmacological reports : PR. vol 58. issue 6. 2007-05-11. PMID:17220541. |
we suggest that nicotine may potentiate the antidepressant-like effects of imipramine by promoting some plastic changes in the brain within dopamine and noradrenaline system considerably more strongly than imipramine alone. |
2007-05-11 |
2023-08-12 |
rat |
| Jason T Ross, William A Corrigall, Christian A Heidbreder, Mark G LeSag. Effects of the selective dopamine D3 receptor antagonist SB-277011A on the reinforcing effects of nicotine as measured by a progressive-ratio schedule in rats. European journal of pharmacology. vol 559. issue 2-3. 2007-05-09. PMID:17303116. |
effects of the selective dopamine d3 receptor antagonist sb-277011a on the reinforcing effects of nicotine as measured by a progressive-ratio schedule in rats. |
2007-05-09 |
2023-08-12 |
rat |
| Jason T Ross, William A Corrigall, Christian A Heidbreder, Mark G LeSag. Effects of the selective dopamine D3 receptor antagonist SB-277011A on the reinforcing effects of nicotine as measured by a progressive-ratio schedule in rats. European journal of pharmacology. vol 559. issue 2-3. 2007-05-09. PMID:17303116. |
at the dose that significantly decreased nicotine self-administration, total distance traveled was also significantly decreased, suggesting that the effect on operant responding at the high dose of sb-277011a is at a threshold for motor effects and may not be directly mediated by an action at dopamine d3 receptors. |
2007-05-09 |
2023-08-12 |
rat |
| K Cahill, L F Stead, T Lancaste. Nicotine receptor partial agonists for smoking cessation. The Cochrane database of systematic reviews. issue 1. 2007-05-08. PMID:17253581. |
nicotine receptor partial agonists may help smokers to quit by a combination of maintaining moderate levels of dopamine to counteract withdrawal symptoms (acting as an agonist) and reducing smoking satisfaction (acting as an antagonist). |
2007-05-08 |
2023-08-12 |
Not clear |
| Shafiqur Rahman, Nichole M Neugebauer, Z Zhang, Peter A Crooks, Linda P Dwoskin, Michael T Bard. The effects of a novel nicotinic receptor antagonist N,N-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB) on acute and repeated nicotine-induced increases in extracellular dopamine in rat nucleus accumbens. Neuropharmacology. vol 52. issue 3. 2007-05-01. PMID:17097117. |
the present study examined the effects of the novel nicotinic acetylcholine receptor (nachr) antagonist, n,n'-dodecane-1,12-diyl-bis-3-picolinium dibromide (bpiddb), after acute and repeated nicotine treatment on extracellular dopamine (da) levels in rat nucleus accumbens (nacc), using in vivo microdialysis. |
2007-05-01 |
2023-08-12 |
rat |
| H Rollema, L K Chambers, J W Coe, J Glowa, R S Hurst, L A Lebel, Y Lu, R S Mansbach, R J Mather, C C Rovetti, S B Sands, E Schaeffer, D W Schulz, F D Tingley, K E William. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology. vol 52. issue 3. 2007-05-01. PMID:17157884. |
in neurochemical models varenicline has significantly lower (40-60%) efficacy than nicotine in stimulating [(3)h]-dopamine release from rat brain slices in vitro and in increasing dopamine release from rat nucleus accumbens in vivo, while it is more potent than nicotine. |
2007-05-01 |
2023-08-12 |
rat |
| H Rollema, L K Chambers, J W Coe, J Glowa, R S Hurst, L A Lebel, Y Lu, R S Mansbach, R J Mather, C C Rovetti, S B Sands, E Schaeffer, D W Schulz, F D Tingley, K E William. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology. vol 52. issue 3. 2007-05-01. PMID:17157884. |
in addition, when combined with nicotine, varenicline effectively attenuates the nicotine-induced dopamine release to the level of the effect of varenicline alone, consistent with partial agonism. |
2007-05-01 |
2023-08-12 |
rat |